OA09317A - "Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour la préparation de compositions pharmaceutiques destinées au traitement des leucémies". - Google Patents

"Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour la préparation de compositions pharmaceutiques destinées au traitement des leucémies".

Info

Publication number
OA09317A
OA09317A OA59870A OA59870A OA09317A OA 09317 A OA09317 A OA 09317A OA 59870 A OA59870 A OA 59870A OA 59870 A OA59870 A OA 59870A OA 09317 A OA09317 A OA 09317A
Authority
OA
OAPI
Prior art keywords
leukaemias
polypeptide
activity
treatment
human
Prior art date
Application number
OA59870A
Other languages
English (en)
French (fr)
Inventor
Brandely Maud
Maraninchi Dominique
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of OA09317A publication Critical patent/OA09317A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA59870A 1989-10-17 1990-10-17 "Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour la préparation de compositions pharmaceutiques destinées au traitement des leucémies". OA09317A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8913546A FR2653020B1 (fr) 1989-10-17 1989-10-17 Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.

Publications (1)

Publication Number Publication Date
OA09317A true OA09317A (fr) 1992-09-15

Family

ID=9386473

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59870A OA09317A (fr) 1989-10-17 1990-10-17 "Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour la préparation de compositions pharmaceutiques destinées au traitement des leucémies".

Country Status (13)

Country Link
US (1) US5582822A (hu)
EP (1) EP0426521B1 (hu)
JP (1) JP2961189B2 (hu)
KR (1) KR0168420B1 (hu)
AT (1) ATE103494T1 (hu)
AU (1) AU640173B2 (hu)
CA (1) CA2027725A1 (hu)
DE (1) DE69007744T2 (hu)
DK (1) DK0426521T3 (hu)
FR (1) FR2653020B1 (hu)
HU (1) HU206048B (hu)
OA (1) OA09317A (hu)
ZA (1) ZA907648B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671728B1 (fr) * 1991-01-17 1995-01-20 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des pneumathorax.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
US6852344B2 (en) * 2000-12-04 2005-02-08 Council Of Scientific And Industrial Research Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof
GB2372598A (en) * 2001-02-26 2002-08-28 Coppereye Ltd Organising data in a database
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US6967034B2 (en) * 2002-05-31 2005-11-22 Council Of Scientific And Industrial Research Herbal-based composition for treating acute and chronic myeloid leukemia
RU2314096C2 (ru) * 2002-05-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Синергическая фармацевтическая композиция для лечения лейкемии
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
US20040006138A1 (en) 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
AU2003266086A1 (en) * 2002-09-16 2004-04-30 Vasogen Ireland Limited Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine)
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US7357652B1 (en) * 2006-10-27 2008-04-15 Leviton Manufacturing Company, Inc. Modular wiring system with locking elements
US8206920B2 (en) * 2007-03-26 2012-06-26 Arnold Ganser Diagnostic assay for the specific treatment of acute myeloid leukemia
US10622768B1 (en) 2019-05-10 2020-04-14 Walter Morgan Cowham Methods and systems for a modular plug-in bus wiring system
US10971879B1 (en) 2020-08-12 2021-04-06 Cowham Innovations, LLC. Electrical connection forming tool
CN111821423B (zh) * 2020-08-17 2023-04-11 中南大学湘雅二医院 一种白介素2用于治疗慢性自发性荨麻疹的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
AU2635088A (en) * 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
ZA898139B (en) * 1988-11-17 1990-08-29 Hoffmann La Roche Recombinant interleukin-2 hybrid proteins

Also Published As

Publication number Publication date
DE69007744T2 (de) 1994-07-28
HU206048B (en) 1992-08-28
ATE103494T1 (de) 1994-04-15
ZA907648B (en) 1991-11-27
EP0426521A1 (fr) 1991-05-08
JP2961189B2 (ja) 1999-10-12
FR2653020A1 (fr) 1991-04-19
DK0426521T3 (da) 1994-05-02
KR0168420B1 (ko) 1999-01-15
AU6466790A (en) 1991-04-26
CA2027725A1 (fr) 1991-04-18
FR2653020B1 (fr) 1993-03-26
JPH03193736A (ja) 1991-08-23
HUT55241A (en) 1991-05-28
HU906463D0 (en) 1991-04-29
DE69007744D1 (de) 1994-05-05
EP0426521B1 (fr) 1994-03-30
KR910007541A (ko) 1991-05-30
AU640173B2 (en) 1993-08-19
US5582822A (en) 1996-12-10

Similar Documents

Publication Publication Date Title
OA09317A (fr) "Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour la préparation de compositions pharmaceutiques destinées au traitement des leucémies".
ATE369383T1 (de) Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor
DE59507920D1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
DE3771509D1 (de) Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
ATE71662T1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
OA09213A (fr) "Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour préparer une composition pharmaceutique destinée au traitement de cancers primitifs de la plèvre".
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
DE69034076D1 (de) Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie
Nishihara et al. Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide
ZA873743B (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
FR2668368B1 (fr) Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
OA09530A (fr) Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour la préparation de compositions pharmaceutiques destinées au traitement des pneumothorax
MERTELSMANN et al. Human interleukin-2
OA09469A (fr) Utilisation d'un polypeptide ayant l'activité de l'interféron gamma pour la préparation de compositions pharmaceutiques destinées au traitement de cancers primitifs de la plèvre.
OA09191A (fr) Utilisation de certains interférons gamma pour la préparation de compositions pharmaceutiques destinées au traitement de cancer de l'ovaire par voie intrapéritonéale.